There has been controversy around aducanumab, which targets the cause rather than the symptoms.
admin, , TOP STORIES, 0
Related Articles
The Download: the case for AI slop, and helping CRISPR fulfill its promise
—Caiwei Chen If I were to locate the moment AI slop broke through into popular consciousness, I’d pick the...
The one-shot vaccine from Johnson & Johnson now has FDA support in the US
That is because in the US, children under 18 make up about a quarter of the population but aren’t...
Geoffrey Hinton has a hunch about what’s next for AI
Deep learning set off the latest AI revolution, transforming computer vision and the field as a whole. Hinton believes...
Big Tech’s attention economy can be reformed. Here’s how.
Seeing reality clearly and truthfully is fundamental to our capacity to do anything. By monetizing and commodifying attention, we’ve...
The Emergent Industrial Metaverse
About the speakers Peter Koerte, CTO and CSO, Siemens AG As Chief Strategy Officer and Chief Technology Officer of...
Why recycling alone can’t power climate tech
For my most recent story, I was researching the materials used for the magnets that power EVs and wind...
